Paras Healthcare Limited (Neutral)

Highlights

Paras Healthcare Limited (PHL) incorporated in 1987, is a clinical specialty-led hospital platform providing tertiary and quaternary healthcare services through a network of eight hospitals under the Paras Health brand, with presence in Gurugram, Patna, Darbhanga, Kanpur, Udaipur, Ranchi and Srinagar.

PHL has built specialty clusters across its hospitals over 20 years, supported by advanced infrastructure, skilled medical talent and standardized care protocols, with specialised focus on high-acuity care across cardiac, oncology, neuro, gastro, orthopedics and sports injury, and renal sciences (CONGOR).

PHL served 894,203 patients in FY26 with an ARPOB of Rs. 47,398, and has scaled its bed capacity from 200 beds in June 2006 to 2,211 beds in June 2026, while a planned addition of 700 beds is expected to take total capacity to 3,011 beds by FY28.

Out of the total proceeds of Rs. 14,500 mn, Rs. 3,750 mn would go towards prepayment or scheduled re-payment of certain outstanding borrowings availed by company and its subsidiary, and remaining Rs. 1,250 mn would go towards funding general corporate purposes. Additionally, Rs. 9,500 mn would go towards promoter and investor selling shareholders of the company. 

Key Highlights

• India’s healthcare delivery market is expected to grow from Rs. 7 trillion in FY25 to Rs. 11.2-12.2 trillion by FY30, at 10-12 pct CAGR. North India is projected to reach Rs. 3.6-3.8 trillion at a CAGR of 10-12 pct. UP, Delhi, Haryana and Rajasthan’s combined market is expected to grow from Rs. 1.7-1.8 trillion to Rs. 2.9-3.1 trillion at 10-12 pct CAGR, while Bihar and Jharkhand are projected to expand from Rs. 0.25-0.7tn to Rs. 0.4-0.5tn, at 9.5-11.5 pct CAGR over same period of time.

• PHL operates through a calibrated mix of owned, leased, revenue-sharing and public-private partnership models, enabling tailored capital deployment to market needs, lower upfront investment, faster market entry and long-term operational control. Expansion decisions are guided by financial return thresholds, balance sheet strength and scalability to ensure disciplined growth.
• PHL categorises its hospitals based on maturity: (i) Mature hospital in Gurugram, Patna, Panchkula, Darbhanga are operational over 7 years, having stable occupancy and consistent margin expansion; (ii) Emerging hospitals in Ranchi, Udaipur are operational between 4 to 7 years with improving occupancy and margins; (iii) and New hospitals at Srinagar and Kanpur are operational for less than 4 years, having lower occupancy but with a huge growth potential.
• PHL aims to drive ARPOB growth and operating leverage at mature hospitals through an optimized specialty and payor mix and a higher share of complex, high-acuity CONGOR cases. Emerging hospitals will focus on improving occupancy and expanding high-acuity clinical programs to drive margins, while new hospitals will ramp up patient volumes through specialty additions, government schemes, insurance empanelment and better utilization of existing equipment.
• PHL intends to expand its network through – (i) Brownfield expansion at its existing hospitals like already added combined 76 beds in Patna and Panchkula, with adjacent land acquired in Panchkula for future expansion; (ii) Greenfield expansion in markets with unment demand through launch of 300 beds Gurugram II Hospital and 500 beds Ludhiana Hospital; and (iii) selective acquisitions to strengthen market presence and operating leverage.
• PHL’s key growth strategies include (i) To scale operations at its hospitals, (ii) expand its network of hospitals in North India Whitespaces, (iii) expand into new and high-end clinical programs supported by advanced technology, (iv) attract and retain qualified and experienced clinicians, and (v) improve operational efficiencies and patient experience
• The sales of the company have grown by 19.26 pct CAGR over FY24-26 and EBITDA has grown by 47.42 pct CAGR, while the bottom line has transitioned into profit from continued losses over same year. In FY26 the company reported sales of Rs. 16,060 mn rose by 24.10 pct YoY. EBITDA of the company rose by 114.48 pct YoY to Rs. 3,356 mn. In FY26 the company posted profit of Rs. 438 mn, which turnaround from previous year loss.

Key Risk

• PHL has significant contingent liabilities accounting for 89.55 pct of net worth, and any event of materialisation could adversely affect its financial position.
• PHL’s empanelment with government health schemes have been subject to adverse actions in the past, including suspension and temporary restrictions, and any further instances like these, may adversely affect its business.
• PHL’s significant revenue comes from government schemes and PSUs creating payment-delay risks, potentially affecting cash flows and the revenue cycle.
• Dependence on advanced medical equipment and hospital infrastructure exposes PHL to operational disruptions from equipment failure or malfunction.

Financial Performance

Source: – RHP.

Peer Comparison based on FY26 Financials.

Source: – RHP.

Valuation

Paras Healthcare Limited (PHL) is a clinical specialty-led hospital platform providing tertiary and quaternary healthcare services through a network of eight hospitals with an aggregate bed capacity of 2,211 beds across North India, Bihar and Jharkhand. They offer several clinical specialties across their hospitals including cardiac sciences, oncology, neuro sciences, gastro sciences and orthopedics and joint replacement. At the upper end of the price band of Rs. 693, the issue is priced at an TTM EV/EBITDA of 23.3x based on its post issue capital. The issue appears to be fully priced.

Disclaimer: The views shared in blogs are based on personal opinions and do not reflect the company’s views. Investment involves risk, and it is advisable to consult a financial advisor before making any investment through the app. The decision to invest is solely that of the investor, and the company or its communication cannot be held responsible for it.